UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PDE5 inhibitors and their applications

Current medicinal chemistry, 2010-08, Vol.17 (24), p.2564-2587

2010

Volltextzugriff (PDF)

[(3-Chlorophenyl)piperazinylpropyl]pyridazinones and Analogues as Potent Antinociceptive Agents

Journal of medicinal chemistry, 2003-03, Vol.46 (6), p.1055-1059

2003

Volltextzugriff (PDF)

Synthesis of 4,5-functionalized-2-methyl-6-(substituted aryl)-3 (2H)-pyridazinones: a new group of potent platelet aggregation inhibitors

Farmaco (Società chimica italiana : 1989), 1997-03, Vol.52 (3), p.173

1997

Volltextzugriff (PDF)

5-Acyl-6-aryl-4-nitro-3(2H)pyridazinones and Related 4-Amino Compounds: Synthesis and Pharmacological Evaluation

Journal of pharmaceutical sciences, 1991-04, Vol.80 (4), p.341-348

1991

Volltextzugriff (PDF)

Antinociceptive activity of a 3(2H)-pyridazinone derivative in mice

Life sciences (1973), 1999, Vol.65 (13), p.1381-1394

1999

Volltextzugriff (PDF)

4-Substituted-5-acetyl-2-methyl-6-phenyl-3(2H)pyridazinones as PGE2 and IL-1 release inhibitors from mouse adherent macrophages

Pharmacological research, 1994-05, Vol.29 (4), p.367-372

1994

Volltextzugriff (PDF)

4-Amino-5-substituted-3(2H)-pyridazinones as Orally Active Antinociceptive Agents: Synthesis and Studies on the Mechanism of Action

Journal of medicinal chemistry, 2007-08, Vol.50 (16), p.3945-3953

2007

Volltextzugriff (PDF)

Indenopyridazinone derivatives as potential antisecretory and antiulcer agents

Drug design and discovery, 1997-08, Vol.15 (2), p.95

1997

Volltextzugriff (PDF)

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients

Neurology, 2012-05, Vol.78 (20), p.1601-1607

2012

Volltextzugriff (PDF)

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Neurology, 2009-02, Vol.72 (5), p.402-409

2009

Volltextzugriff (PDF)

Autonomous and self-sustained circadian oscillators displayed in human islet cells

Diabetologia, 2013-03, Vol.56 (3), p.497-507

2013

Volltextzugriff (PDF)

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2013-06, Vol.381 (9884), p.2167-2175

2013

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

The New England journal of medicine, 2006-03, Vol.354 (9), p.899-910

2006

Volltextzugriff (PDF)

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

The New England journal of medicine, 2010-02, Vol.362 (5), p.416-426

2010

Volltextzugriff (PDF)

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

Neurology, 2007-04, Vol.68 (17), p.1390-1401

2007

Volltextzugriff (PDF)

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

The New England journal of medicine, 2024-02, Vol.390 (7), p.589-600

2024

Volltextzugriff (PDF)

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

Lancet neurology, 2014-05, Vol.13 (5), p.472-481

2014

Volltextzugriff (PDF)

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management

European journal of neurology, 2018-05, Vol.25 (5), p.739-746

2018

Volltextzugriff (PDF)

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

The Lancet (British edition), 2012-11, Vol.380 (9856), p.1829-1839

2012

Volltextzugriff (PDF)

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

Multiple sclerosis, 2011-05, Vol.17 (5), p.578-593

2011

Volltextzugriff (PDF)

Subtle motor disturbances in PREDICT-PD participants

Journal of neurology, neurosurgery and psychiatry, 2017-03, Vol.88 (3), p.212-217

2017

Volltextzugriff (PDF)

Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case–control study in an English population-based cohort

Journal of neurology, 2024-01, Vol.271 (1), p.241-253

2024

Volltextzugriff (PDF)

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

The Lancet (British edition), 2008-10, Vol.372 (9648), p.1463-1472

2008

Volltextzugriff (PDF)

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

Journal of neurology, neurosurgery and psychiatry, 2016-02, Vol.87 (2), p.126-129

2016

Volltextzugriff (PDF)

Disease-associated astrocyte epigenetic memory promotes CNS pathology

Nature (London), 2024-03, Vol.627 (8005), p.865-872

2024

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(59)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(51)
Science & Technology
(49)
Life Sciences & Biomedicine
(47)
Female
(45)
Adult
(35)
Middle Aged
(31)
Biological And Medical Sciences
(30)
Medical Sciences
(29)
Neurosciences & Neurology
(25)
Clinical Neurology
(24)
Neurology
(20)
Adolescent
(19)
Multiple Sclerosis
(18)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(16)
Animals
(15)
Magnetic Resonance Imaging
(14)
Pharmacology. Drug Treatments
(12)
Neurosciences
(11)
Treatment Outcome
(11)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PDE5 inhibitors and their applications

[(3-Chlorophenyl)piperazinylpropyl]pyridazinones and Analogues as Potent Antinociceptive Agents

Synthesis of 4,5-functionalized-2-methyl-6-(substituted aryl)-3 (2H)-pyridazinones: a new group of potent platelet aggregation inhibitors

5-Acyl-6-aryl-4-nitro-3(2H)pyridazinones and Related 4-Amino Compounds: Synthesis and Pharmacological Evaluation

Antinociceptive activity of a 3(2H)-pyridazinone derivative in mice

4-Substituted-5-acetyl-2-methyl-6-phenyl-3(2H)pyridazinones as PGE2 and IL-1 release inhibitors from mouse adherent macrophages

4-Amino-5-substituted-3(2H)-pyridazinones as Orally Active Antinociceptive Agents: Synthesis and Studies on the Mechanism of Action

Indenopyridazinone derivatives as potential antisecretory and antiulcer agents

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Autonomous and self-sustained circadian oscillators displayed in human islet cells

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

Subtle motor disturbances in PREDICT-PD participants

Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case–control study in an English population-based cohort

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

Disease-associated astrocyte epigenetic memory promotes CNS pathology

Aktive Filter

Suchergebnisse filtern